Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma

  title={Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma},
  author={Mustafa Çetin and Deniz Demirci and Ali {\"U}nal and Mustafa Altınbaş and Muhammed G{\"u}ven and K{\"u}rsat {\"U}nl{\"u}hizarci},
  journal={Human and Experimental Toxicology},
  pages={137 - 140}
To identify and describe the frequency and severity of hepatotoxicity in patients who received flutamide therapy for prostate cancer, 22 patients were treated with the combination of flutamide and goserilin or orchiectomy. After diagnosis and staging of prostate cancer, baseline results were obtained for a set of five liver function tests (LF Ts). Hepatotoxicity was assessed according to the WHO criteria. After initiation of flutamide therapy, LF Ts were performed at 4, 8 and 12 weeks and every… 

Tables from this paper

Flutamide-induced hepatotoxicity: a case report.
The case of a 55-year-old male with prostatic adenocarcinoma who developed liver failure after six months of flutamide therapy and ursodeoxycholic acid (UDCA) was reported, it appeared that UDCA was an effective therapy forFlutamide hepatotoxicity.
Flutamide Induced Liver Injury in Female Patients
It is important to emphasize that flutamide can cause severe side effects, above all liver damage, so it is not justified to use it in the treatment of conditions other than prostate cancer, so a review of the literature with case reports of notably hepatotoxicity is presented along with a case from clinical practice.
Cholestatic hepatitis induced by flutamida: Presentation of a case
Even though Flutamide is a safe and well-tolerated medi-cation, it is not exempt from adverse effects and produces pneumonitis caused by hypersensitivity, pulmonary embolism, jaundice, hepatitis and hepatic failure.
Microscopic Polyangiitis Complicated by the Development of Prostate Cancer and Flutamide-induced Hepatitis
It is suggested that patients with vasculitis or other autoimmune disorders should avoid prolonged use of cyclophosphamide and other cytotoxic drugs in order to minimize long-term adverse effects, and the risk of cancer is by far the most important.
Flutamide-induced hepatotoxicity: ethical and scientific issues.
Scientific contributions highlight that FLU is responsible for specific hepatotoxic profiles in the female gender and off-label prescribing of FLU in women is not only substantially unlawful, but also, without major safeguards being granted, a potential source of liability for prescribers.
Hepatotoxicity Induced by Antiandrogens: A Review of the Literature
Although there are differences in the clinical features of hepatotoxicity induced by steroidal and nonsteroidal antiandrogens, these do not predict which patients will develop hepatot toxicity during treatment or evolution.
Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites
It is proposed that plasma FLU-1 levels are one of the predictive factors for flutamide-induced hepatic dysfunction, and this hypothesis will be confirmed in a large-scale study.
CASE REPORT: Toxic Hepatitis After Sequential Administration of Flutamide and Cyproterone Acetate
Arguments against the practice of starting treatment with one agent when the other has to be discontinued due to hepatoxicity are raised.
Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen
No benefit in survival was found with antiandrogenic treatment in male patients with advanced HCC, mainly because of digestive side effects.


Flutamide-induced liver toxicity including fatal hepatic necrosis.
Flutamide hepatotoxicity.
Flutamide is a potent hepatotoxin in certain patients and before beginning use of this drug patients should be instructed to report immediately to physicians any episodes of nausea, vomiting, fatigue and jaundice so that flutamide can be promptly discontinued to avoid progression of possible liver injury.
Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
Flutamide toxicity was common in patients treated with total androgen suppression before and during pelvic radiation therapy (RT) for prostate cancer, and LFTs should be monitored during flutamide therapy.
Fatal and Nonfatal Hepatotoxicity Associated with Flutamide
This article summarizes reports submitted to the Food and Drug Administration of patients with hepatotoxicity that may have been caused by flutamide and reviews reports that originated in domestic patient care settings.
Flutamide-induced liver failure.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
EORTC Protocol 30853: Orchidectomy Versus Zoladex Plus Flutamide in the Management of Metastatic Carcinoma of the Prostate
The toxicity and side effects of combination therapy with zoladex and flutamide have not been excessive compared with those due to orchidectomy and treatment modification has been necessary in 12 of the 149 patients receiving the combination therapy.